A comprehensive view of Janssen Pharmaceutical Companies. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Janssen Pharmaceutical Drives Industry Innovation with New Ulcerative Colitis Research, Gene Therapy Discussions, Advances in Lung Cancer Therapeutics, and Initiatives on Health Equity

CHMP recommends approval of Janssen's CARVYKTI cilta-cel for earlier treatment of relapsed and refractory multiple myeloma; this marks the first time a CAR-T therapy has received a positive CHMP opinion for this patient population post first relapse

FDA approves J&J's supplemental application for a reduced dosing regimen of TECVAYLI, an injectable medicine for patients with relapsed or refractory multiple myeloma; the approval will enable biweekly, weight-based dosing, adding flexibility for patients

Janssen Pharmaceutical Companies Advancing Inclusive Oncology Clinical Trials and Non-Surgical Solutions in Maternal-Fetal Immunology

Janssen Pharmaceutical's Breakthrough Designation Spearheads Vital Innovations in Maternal-Fetal Medicine

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count